ArticlePathology oncology research : POR2022

Case Report: Specific ABL-Inhibitor Imatinib Is an Effective Targeted Agent as the First Line Therapy to Treat B-Cell Acute Lymphoblastic Leukemia With a Cryptic

Egle Stukaite-Ruibiene et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.